ESTA Filings — Establishment Labs Holdings Inc. - FilingSpy
ESTA
Establishment Labs Holdings Inc.
A maker of breast implants and aesthetic medical devices, Establishment Labs produces the Motiva line of silicone-gel implants and the Motiva Flora tissue expander, sold in over 100 countries. Founded in 2004 by Juan José Chacón-Quirós, who started the company in his parents' house in Costa Rica, it became the first Costa Rican medtech firm to list on the Nasdaq in 2018. The Motiva brand name comes from the word "motive," reflecting the company's mission to put women's health first.
U.S. sales of Motiva Implants more than doubled year over year, driving Q2 revenue up 32% to $67.5M.
The U.S. launch of Motiva Implants continued to reshape the business. rose 31.7% to $67.5 million and reached 70.6% as higher-priced U.S. direct sales grew to become the dominant driver, while the operating loss narrowed to $4.3 million from $14.1 million a year ago. The company refinanced its debt after the quarter, extending its runway as it scales the U.S. market.
Key takeaways
rose 31.7% to $67.5 million, a quarterly record, driven by the U.S. commercial launch of Motiva Implants following the September 2024 FDA approval.
widened 1.9 points to 70.6%, which management attributed to favorable geographic mix and higher average selling prices in the U.S. direct-sales channel.
The operating loss narrowed to $4.3 million from $14.1 million a year ago, as the $16.2 million increase in more than offset higher operating expenses tied to the U.S. expansion.
Section summaries
Management's Discussion and Analysis
Revenue rose 37.5% to $127.4M in H1 2026, driven by U.S. sales, while net loss narrowed to $25.1M.
⌄
for H1 2026 grew 37.5% to $127.4M, with U.S. sales contributing $27.9M of the $34.7M increase.
improved to 70.7% from 68.1%, helped by favorable geographic mix and higher U.S. selling prices.
SG&A expense rose 7.9% to $90.5 million for the first half, driven by higher professional fees, personnel costs, and sales commissions, and consumed 71% of H1 .
Net loss narrowed to $11.7 million from $16.6 million a year ago, aided by growth and a $7.4 million swing in other income and expense.
After the quarter, the company refinanced its debt with a new $300 million credit agreement, drawing $265 million to repay $259 million of prior obligations, and stated it believes current cash and operations can fund needs for at least 12 months.
What changed
Q2 2026 U.S. continued to accelerate, with total revenue reaching a record $67.5 million, up 12.8% sequentially from $59.9 million in Q1 2026, confirming the ramp flagged in prior quarters.
SG&A as a percentage of fell to 71% in H1 2026 from 90.5% in H1 2025, as revenue growth from the U.S. launch began to outpace the increase in launch-related spending.
Operating cash outflow was $16.6 million in Q2 2026, higher than the near-breakeven $4.3 million in Q1 2026, but the post-quarter debt refinancing alters the liquidity picture flagged in prior periods.
The in internal control over financial reporting related to IT change management remains unaddressed, with no update provided on its remediation.
What to watch
Q3 2026 U.S. to gauge whether the sequential growth from Q1 to Q2 continues and whether the U.S. sustains its position as the largest single market.
SG&A expense as a percentage of in Q3 2026, to assess whether the 71% H1 ratio holds or declines further as U.S. launch costs scale.
Q3 2026 and cash balance, to measure the impact of the post-quarter debt refinancing on the cost of debt and liquidity runway.
Any update on the remediation of the in internal control over financial reporting, the absence of which leaves a known deficiency unaddressed.
expense rose 7.9% to $90.5M, driven by higher professional fees, personnel costs, and sales commissions.
Net loss narrowed to $25.1M from $37.3M, aided by growth and a $7.4M swing in other income/expense.
The company refinanced debt with a new $300M credit agreement, drawing $265M to repay prior obligations.
Cash used in operations was $20.9M; management believes current cash and operations can fund needs for at least 12 months.
Quantitative and Qualitative Disclosures About Market Risk
Our exposure to market risk during the six months ended June 30, 2026 has not materially changed from what was previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. See Part II, Item 7A, Quantitative and Qualitative Disclosures About…
⌄
Our exposure to market risk during the six months ended June 30, 2026 has not materially changed from what was previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. See Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk in our Annual Report on Form 10-K for the year ended December 31, 2025 for additional information.
Establishment Labs is defending patent validity and asserting infringement against Silimed and GCA Group across Brazil, Europe, and the UK.
⌄
Silimed filed a patent nullity suit in Brazil in July 2025 seeking to invalidate ELSA's Process Patent for SmoothSilk implant surface manufacturing.
ELSA countersued Silimed for patent infringement in Brazil in August 2025; both Brazilian cases expect merits hearings around mid-2027.
ELSA sued GCA Group for infringement of its European UPC Patent in Belgium; GCA filed a defense and revocation counterclaim, with a merits hearing set for December 2026.
GCA (Brazil) filed a UK revocation action against ELSA's UK Patent; ELSA counterclaimed for infringement against four GCA defendants, with a liability trial set for April 2027.
The Company states it cannot predict outcomes and warns that adverse resolutions could materially harm its business, financial condition, or cash flows.
We have described under the heading “Risk Factors” included in Part I, Item 1A. in our Form 10-K filed with the SEC on February 27, 2026, a number of risks and uncertainties that could cause our actual results of operations and financial condition to vary materially from past, o…
⌄
We have described under the heading “Risk Factors” included in Part I, Item 1A. in our Form 10-K filed with the SEC on February 27, 2026, a number of risks and uncertainties that could cause our actual results of operations and financial condition to vary materially from past, or from anticipated future, results of operations and financial condition. There have been no material changes from these risk factors previously described in our Form 10-K filed with the SEC on February 27, 2026. These risks and uncertainties are not the only risks facing us. Additional risks and uncertainties not presently known to us or that we currently deem not material may also adversely affect our business, financial condition, results of operations or the market price of our common stock.